 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Martin Krsak and Kyle Molina.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.016 |
|
|
|
-
Krsak M, Scherger S, Miller MA, Cobb V, Montague BT, Henao-Mart?nez AF, Molina KC. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study. Ther Adv Infect Dis. 2024 Jan-Dec; 11:20499361231223889.
Score: 0.979
-
Molina KC, Mueller SW, Miller MA, Krsak M. Response to Mahatanan and Kang: It's Complicated. Open Forum Infect Dis. 2023 May; 10(5):ofad210.
Score: 0.930
-
Molina KC, Lunowa C, Lebin M, Segerstrom Nunez A, Azimi SF, Krsak M, Mueller SW, Miller MA. Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections. Open Forum Infect Dis. 2022 Jul; 9(7):ofac335.
Score: 0.220
-
Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clin Pharmacokinet. 2022 03; 61(3):363-374.
Score: 0.212
-
Mueller SW, Kedzior SK, Miller MA, Reynolds PM, Kiser TH, Krsak M, Molina KC. An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections. Expert Opin Pharmacother. 2021 Jul; 22(10):1355-1371.
Score: 0.202
-
Krsak M, Morrisette T, Miller M, Molina K, Huang M, Damioli L, Pisney L, Wong M, Poeschla E. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. Pharmacotherapy. 2020 05; 40(5):469-478.
Score: 0.189
-
Texidor WM, Miller MA, Molina KC, Krsak M, Calvert B, Hart C, Storer M, Fish DN. Oritavancin as sequential therapy for Gram-positive bloodstream infections. BMC Infect Dis. 2024 Jan 24; 24(1):127.
Score: 0.061
-
Mueller SW, Blass B, Molina KC, Gibson C, Krsak M, Kohler AD, Deeter L, Stalilonis J, Wiktor AJ. Augmented Renal Function in Burn Patients: Occurrence and Discordance With Commonly Used Methods to Assess Renal Function. J Burn Care Res. 2023 11 02; 44(6):1298-1303.
Score: 0.060
-
Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. Open Forum Infect Dis. 2022 Jun; 9(6):ofac028.
Score: 0.055
-
Hoover RK, Krsak M, Molina KC, Shah K, Redell M. Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties. Open Forum Infect Dis. 2022 May; 9(5):ofac090.
Score: 0.054
-
Novak AR, Krsak M, Kiser TH, Neumann RT, Cava Prado L, Molina KC, Mueller SW. Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients. Open Forum Infect Dis. 2022 Feb; 9(2):ofab649.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|